Prelude PRT7732

{ "short_title": "Prelude PRT7732", "data_mode": "900", "data_mode_number": "000002470", "official_title": "A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": "NCT06560645", "eudract_number": "2024-512380-32", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Dies ist eine Phase-1-Studie zur Bestimmung der Sicherheit, Vertr\u00e4glichkeit, Pharmakokinetik, Pharmakodynamik und vorl\u00e4ufigen Wirksamkeit von PRT7732 bei Patienten mit ausgew\u00e4hlten fortgeschrittenen oder metastasierenden soliden Tumoren mit einer SMARCA4-Mutation.", "description_laie_en": "This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics,pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced ormetastatic solid tumors with a SMARCA4 mutation.", "description_expert_de": "Dies ist eine Phase-1-Studie zur Bestimmung der Sicherheit, Vertr\u00e4glichkeit, Pharmakokinetik, Pharmakodynamik und vorl\u00e4ufigen Wirksamkeit von PRT7732 bei Patienten mit ausgew\u00e4hlten fortgeschrittenen oder metastasierenden soliden Tumoren mit einer SMARCA4-Mutation.", "description_expert_en": "This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics,pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced ormetastatic solid tumors with a SMARCA4 mutation.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 10, "sub_cat_id": 50 }